US Patent 10,195,375 (Airflow adaptor and deagglomerator for breath-actuated dry powder inhalers): scope, claim-by-claim coverage, and US patent landscape
US 10,195,375 is directed to a breath-actuated dry powder inhaler (DPI) architecture in which an “airflow adaptor” at the deagglomerator outlet includes a bypass airflow path that is hydraulically independent from the main deagglomerator outlet conduit under breath-induced low pressure. The core novelty is structural: a first conduit from the deagglomerator outlet to a distal adaptor end with a first aperture in a circumferential flange, plus at least one second conduit that is “in the form of” (i) one or more second apertures in that circumferential flange (and/or ii) second apertures in a proximal circumferential flange), with a functional airflow split threshold of at least 5% of resulting airflow passing through the second conduit(s) during inhalation.
This claim set is broad at the system level (airflow adaptor, deagglomerator, and breath-actuated DPI), and it includes specific quantitative limitation hooks (cross-sectional area ratio / ≥5% airflow through bypass) that narrow validity/coverage for close designs. The downstream product claims tie the inhaler to both generic deagglomerator swirl-chamber constructs and optional medicament classes, including fluticasone propionate and fluticasone propionate/salmeterol xinafoate.
What is the invention scope of US Patent 10,195,375 (airflow adaptor and bypass conduits in breath-actuated DPIs)?
Direct technical scope
US 10,195,375 claims components and combinations used in breath-actuated DPIs:
-
Airflow adaptor (primary independent concept)
- First conduit: proximal end communicates from a deagglomerator outlet port to a distal end of the first conduit that sits at the distal end of the adaptor.
- Distal end includes a first aperture in a first circumferential flange.
- Second conduit(s): one or more bypass conduits configured to allow air flow from the proximal end of the adaptor to the distal end independently of airflow in the first conduit when a breath-induced low pressure is applied at the distal end.
- Second conduit in the form of at least one second aperture in the first circumferential flange.
-
Quantified bypass split limitation
- In dependent claims, the bypass is not merely present; it is apportioned so that when suction is applied, at least 5% of resulting airflow flows through the second conduit(s), expressed as a ratio of cross-sectional areas:
- Sum of second conduit cross-sectional areas divided by first conduit cross-sectional area.
-
Deagglomerator integration (swirl chamber + inlet/outlet ports)
- Deagglomerators include:
- an inner wall defining a swirl chamber
- a dry powder supply port at the first end
- at least one inlet port adjacent the first end providing communication with an exterior region
- an outlet port at the second end
- Claims then integrate the airflow adaptor:
- outlet port to adaptor via first conduit aperture at distal flange, plus bypass conduit/apertures that bypass the swirl chamber.
-
System-level inhaler claims
- The breath-actuated DPI comprises the airflow adaptor and/or the deagglomerator.
- Medicament limitations appear in later dependent claims as class-based and then species-based limitations:
- anti-inflammatory, anti-cholinergic, β2-agonist, anti-infective, antihistamine, combinations
- specifically fluticasone propionate
- specifically fluticasone propionate + salmeterol xinafoate
Functional scope that matters for design-around
The claims are not purely mechanical. They require the bypass path to become active under suction:
- The second conduit(s) provide airflow from proximal to distal end independently of first conduit airflow when breath-induced low pressure is applied to the adaptor distal end.
- In multiple places, they require a bypass effectiveness threshold (≥5% of resulting airflow).
What do claim 1 and claim 2 cover in US 10,195,375 (airflow adaptor with first aperture and bypass apertures)?
Claim 1 (independent): airflow adaptor architecture
Key elements (coverage anchor):
- Airflow adaptor for breath-actuated DPI.
- First conduit: proximal end allows fluid communication from deagglomerator outlet port to distal end.
- Second conduit(s): allow air to flow from proximal end to distal end independently of first conduit when breath-induced low pressure applied to distal end.
- Distal end of first conduit is at distal end of adaptor and comprises:
- first aperture in first circumferential flange
- Second conduit is:
- in the form of at least one second aperture in the first circumferential flange
What this means in practice
A competitor’s adaptor is most at risk if it:
- places both a main opening and bypass opening(s) on a circumferential flange at the adaptor distal region, and
- implements bypass airflow paths that are not simply the same flow path as the deagglomerator outlet conduit, but are independently fed from the adaptor proximal side under inhalation suction.
Claim 2 (dependent): ≥5% bypass airflow constraint
- Ratio limitation:
- (sum of cross-sectional areas of at least one second conduit) / (cross-sectional area of first conduit)
- is such that at least 5% of resulting airflow passes through the second conduit(s) under breath-induced low pressure.
Claim 2 is a quantization of “independently”
It reduces risk that a “bypass” is merely nominal or choked. For infringement, the adaptor’s geometry must support the threshold bypass fraction.
What additional structural limitations do claims 3–5 add (multi-aperture flanges and second flange variants)?
Claim 3 (dependent)
- First circumferential flange comprises at least two second apertures.
- This narrows to designs where the second conduit is plural.
Claim 4 (dependent)
- A second circumferential flange at the proximal end.
- First conduit comprises a first aperture.
- Second circumferential flange further comprises at least one second aperture that forms part of the second conduit.
Design implication
This is a variant where bypass apertures are associated with a proximal flange rather than (or in addition to) the distal flange arrangement, depending on construction.
Claim 5 (dependent)
- Applies a similar ≥5% cross-sectional area ratio concept:
- (sum cross-sectional areas of second apertures in second circumferential flange) / (cross-sectional area of first conduit)
- yields at least 5% bypass airflow under breath-induced low pressure.
What deagglomerator scope is captured by claims 6–11 (swirl chamber plus airflow adaptor bypass)?
Claim 6 (dependent)
- Deagglomerator comprising the airflow adaptor of claim 1.
Claim 7 (dependent)
- Deagglomerator includes swirl chamber + powder supply port + inlet port(s) near first end + outlet port to airflow adaptor.
- Breath-induced low pressure at distal adaptor end causes air to flow into swirl chamber through powder supply port and inlet port.
Note: Claim 7 emphasizes the swirl chamber filling flow paths, not bypass fraction.
Claim 8 (independent): deagglomerator with bypass that “by-passes the swirl chamber”
This is a second major independent claim family member (based on the claim numbering you provided, claim 8 reads like an independent claim for deagglomerator).
Key elements:
- Swirl chamber architecture as in claim 7.
- Outlet port communicates with airflow adaptor:
- airflow adaptor provides communication between outlet port and exterior via a first conduit
- distal end of first conduit at adaptor distal end includes first aperture in first circumferential flange
- Second conduit(s) bypass swirl chamber and direct air from adaptor proximal end to distal end independently of first conduit
- Second conduit comprises second aperture in first circumferential flange
Design implication
The claims expressly require bypassing the swirl chamber (not just splitting flow downstream). For infringement, a competitor must have an internal flow path that avoids the swirl chamber and routes air directly (or at least outside the swirl chamber region) to the distal adaptor region.
Claim 9 (dependent)
- Breath-induced low pressure causes air to flow into swirl chamber through powder supply port and inlet port.
Claim 10 (dependent): ≥5% bypass based on outlet port geometry
- The ratio:
- sum cross-sectional area of second conduit(s) / cross-sectional area of outlet port
- must support at least 5% of resulting airflow through second conduit(s) under suction.
Claim 11 (dependent)
- Second conduit is at least one second aperture in first circumferential flange.
How broad are the inhaler product claims 12–21 (including fluticasone and fluticasone/salmeterol)?
Claim 12 (independent): breath-actuated DPI comprising airflow adaptor
- The inhaler comprises an airflow adaptor according to claim 1.
Claim 14 (independent): breath-actuated DPI comprising deagglomerator
- The inhaler comprises a deagglomerator according to claim 8.
These product claims create high-value infringement hooks for any manufacturer selling a breath-actuated DPI that includes the claimed adaptor or deagglomerator.
Medicaments (claims 13, 15–21)
- Claims 13 and 15 are generic: inhaler includes a dry powder medicament.
- Claims 16 and 19 limit to active ingredient class selections:
- anti-inflammatory agent, anti-cholinergic, β2-adrenoreceptor agonist, anti-infective, antihistamine, and combinations
- Claim 17: active ingredient comprises fluticasone propionate
- Claim 18: combination fluticasone propionate + salmeterol xinafoate
The same family appears to be repeated for deagglomerator-based inhaler (claims 19–21).
Coverage analysis for medicament-limited claims
Even if an inhaler’s mechanism matches claims 12 or 14, infringement of the medicament-limited claims requires the presence of the specified active(s). However, the existence of earlier independent mechanical claims means enforcement can proceed even if the medicament is different (subject to claim construction of the earlier “inhaler comprises…” elements).
What is the practical claim coverage map for infringement risk? (adaptor vs bypass vs swirl chamber vs medicament)
| Claim cluster |
What it requires (infringement essentials) |
Primary infringement surface |
| Claim 1 + 2 |
First conduit from deagglomerator outlet to distal flange aperture; second bypass conduit via one or more apertures in flange; bypass acts independently under suction; optionally ≥5% split |
Airflow adaptor component design |
| Claims 3–5 |
Adds multiplicity of apertures and/or proximal flange variant |
Adaptor flange design details |
| Claim 6–7 |
Deagglomerator includes claimed adaptor; swirl chamber air feeding via powder supply port and inlet port |
Deagglomerator chamber + adaptor integration |
| Claim 8 + 10–11 |
Bypass that “by-passes the swirl chamber,” routes air from proximal to distal independent of first conduit; second conduit via apertures at distal flange; optionally ≥5% split based on outlet port |
Deagglomerator internals + adaptor |
| Claims 12–14 |
Inhaler includes claimed adaptor or claimed deagglomerator |
Product-level packaging/manufacturing |
| Claims 16–21 |
Medicament class/species and combination |
Brand-specific enforcement |
How many independent claim “paths” exist (and how do they affect invalidity/attack strategy)?
Based on the claim text provided, the independent coverage paths are at least:
- Airflow adaptor independent claim: claim 1
- Deagglomerator independent claim: claim 8 (constructed as independent)
- Inhaler independents: claim 12 and claim 14
This matters because an accused product can potentially be captured via:
- adaptor inclusion (claims 1/12) even if swirl chamber integration differs, or
- deagglomerator inclusion (claims 8/14) even if adaptor-only argument is less direct, or
- medicament-specific claims (claims 16–21) if the actives match.
For patentability and litigation strategy, the quantitative bypass thresholds (claims 2, 5, 10) become focal narrowing limitations that can also be used to distinguish prior art if earlier disclosures do not teach an aperture-based bypass achieving ≥5% split under inhalation suction.
US patent landscape question: what US prior art is most relevant to these claim features?
Without a verified citation set for US 10,195,375 and its family, the relevant landscape can only be characterized structurally based on claim elements likely to be found in DPI mechanics prior art:
Prior art clusters likely to be relevant
-
Breath-actuated DPI deagglomerators with swirl chambers
- Swirl chamber geometries, inlet ports for entrainment, powder supply port at chamber inlet, and outlet conduits to airflow adaptors.
-
Airflow splitters or bypass flows in DPIs
- Devices that introduce “extra” air via additional apertures or passages to modulate aerosolization and deagglomeration.
-
Aperture/porting in circumferential flanges at outlet regions
- Adapter plates and multi-aperture flanges that distribute airflow at the interface between internal deagglomeration regions and downstream mouthpiece/turbulence/transport pathways.
-
Airflow independence concepts under suction
- Prior art may disclose two flow channels, but not necessarily “independent” operation tied to suction at a distal end, as written.
-
Quantified bypass fraction thresholds
- The ≥5% requirement is a specific quantitative limitation that is less likely to appear verbatim in older mechanical DPI patents unless the prior art provides measurable split ratios or comparable airflow partition metrics.
Landscape conclusion at the feature level
The closest prior art for validity and design-around will be DPI systems that already have:
- swirl chambers for deagglomeration, and
- a secondary airflow entry path at or near the downstream interface,
but the dispositive difference for this patent family is the claim’s combination of:
- bypass conduit implemented as apertures in circumferential flange(s), and
- suction-driven independent flow, and
- at least one claim requiring a ≥5% bypass fraction.
What is the litigation and regulatory posture for US 10,195,375 (Orange Book, Paragraph IV, biosimilar risk)?
No Orange Book, Orange Book listing status, or Paragraph IV litigation history can be asserted from the information provided. US 10,195,375 relates to device mechanics within DPIs; Paragraph IV is only relevant if tied to a specific FDA-approved drug product and if that product is listed in the Orange Book with a patent that covers the relevant formulation/device claims. The claim text you provided references specific active ingredients (fluticasone propionate; fluticasone propionate/salmeterol xinafoate), but that alone is not sufficient to map the patent to a listed NDA.
Biosimilar risk is not directly applicable because the claims are for a small-molecule DPI device architecture, not a biologic.
Generic entry risk scenarios for breath-actuated DPIs under US 10,195,375 (how would a generic or competitor design around)?
Scenario A: competitor copies the adaptor flange but changes flow split
- If bypass apertures exist but do not satisfy the ≥5% split limitation (claims 2/5/10), infringement of the narrower dependent claims may be avoided.
- However, independent claims 1 and 8 still require functional independence and structural bypass via apertures in the circumferential flange, without necessarily the ≥5% metric.
Scenario B: bypass exists but does not bypass the swirl chamber
- If a competitor’s second path recirculates air into the swirl chamber (or routes through it), it may defeat the “by-passes the swirl chamber” limitation in claim 8.
- Claim 1 could still be implicated if the adaptor-level structure and independence under suction are present.
Scenario C: circumferential flange apertures are replaced with non-aperture channels
- Claim 1 and 8 strongly tether “second conduit” to apertures in circumferential flange(s).
- Moving the bypass to different geometry (e.g., separate manifold not using flange apertures at the specified location) can be a primary design-around strategy.
Scenario D: system uses different deagglomerator architecture
- If the competitor’s deagglomerator lacks the swirl chamber + inlet/outlet port arrangement, claim 8 and dependent deagglomerator claims are less likely to read.
- Adaptor-only independent claim 1 can still capture an inhaler that includes a matching airflow adaptor.
Key takeaways
- US 10,195,375 centers on a bypass airflow adaptor where a second conduit is implemented as apertures in a circumferential flange, providing independent airflow under suction applied at the adaptor distal end.
- Claims 2, 5, and 10 add quantitative bypass effectiveness constraints requiring at least 5% of resulting airflow through the bypass path.
- The deagglomerator claims require a swirl chamber and a bypass that “by-passes the swirl chamber” (claim 8), tying the adaptor architecture to internal deagglomeration mechanics.
- Inhaler claims extend the coverage to breath-actuated DPIs; later dependent claims narrow to specific medicaments including fluticasone propionate and fluticasone/salmeterol.
- Enforcement leverage is highest against products that incorporate the claimed adaptor and/or deagglomerator architecture; design-around is most feasible by altering (i) flange-aperture bypass implementation, (ii) independence under suction, (iii) bypass routing relative to the swirl chamber, and/or (iv) bypass airflow fraction.
FAQs
What features of the airflow adaptor are essential in US 10,195,375 to infringe claim 1?
A first conduit from the deagglomerator outlet to a distal flange aperture, plus a second bypass conduit routed independently under suction, where the second conduit is “in the form of” second apertures in the circumferential flange.
Does US 10,195,375 require the second conduit to bypass the swirl chamber?
Yes for the deagglomerator independent claim (claim 8), which expressly states the second conduit “by-passes the swirl chamber.”
How does the ≥5% airflow limitation affect infringement and design-around?
It narrows dependent claim scope: a product that otherwise matches the adaptor structure but yields less than 5% bypass airflow may avoid infringement of the dependent quantitative claims, while still potentially facing the broader independent adaptor/deagglomerator claims.
Can an inhaler avoid the patent by using a different medicament?
Changing medicament can avoid medicament-specific dependent claims (fluticasone propionate; fluticasone/salmeterol) but does not avoid adaptor and deagglomerator independent coverage if the claimed mechanics are present.
Are there separate infringement theories for the adaptor versus the inhaler product?
Yes. The patent provides component-level coverage (airflow adaptor; deagglomerator) and product-level coverage (breath-actuated DPI comprising the adaptor/deagglomerator).
